Command Palette

Search for a command to run...

MANKIND
2646.3(+0.30%)
1W: +1.89%

Peers

Snapshot Summary

Mankind Pharma Ltd. showcases strong profitability and growth relative to its peers, while maintaining low debt levels, making it an attractive pick in the Pharmaceuticals & Drugs industry. However, it has a relatively high valuation compared to its growth prospects, suggesting a balanced outlook with potential caution for new investors.

  • • Mankind Pharma has the highest revenue growth YoY (18.12%) and strong EPS growth (48.24%).
  • • Dr. Reddy's Laboratories ranks highest in profitability metrics like ROE (21.76%) and EBITDA margin (27.09%).
  • • Mankind has a low debt-equity ratio (0.021), indicating strong financial stability.
  • • Mankind Pharma Ltd.: Highest revenue growth YoY (18.12%) and strong EPS growth (48.24%).
  • • Dr. Reddy's Laboratories Ltd.: Highest ROE (21.76%) and significant profitability with low valuation metrics.
  • • Cipla Ltd.: Best valuation attractiveness with a low PE (23.73) and high profitability.
Stocks
CMP
Market Cap
P/E
ROCE (%)
Debt/Equity
MANKIND₹2,518.95₹1,03,926.59Cr55.1828.38%0.02
SUNPHARMA₹1,563.35₹3,75,099.26Cr87.5917.60%0.04
DIVISLAB₹6,091.05₹1,61,698.50Cr73.2016.46%-
CIPLA₹1,587.60₹1,28,217.27Cr23.7322.77%0.01
TORNTPHARM₹3,581.55₹1,21,215.77Cr61.5324.28%0.57
DRREDDY₹1,280.30₹1,06,835.27Cr15.5026.86%0.07
ZYDUSLIFE₹990.65₹99,682.17Cr17.2624.90%0.04
Explore
Watchlists
Chat
Portfolio